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ORIGINAL ARTICLE VIROLOGYImmune-driven adaptation of hepatitis B virus genotype D involves
preferential alteration in B-cell epitopes and replicative attenuation—an
insight from human immunodeﬁciency virus/hepatitis B virus coinfectionR. K. Mondal1, M. Khatun1, S. Ghosh1, P. Banerjee1, S. Datta1, S. Sarkar1, B. Saha2, A. Santra1, S. Banerjee1, A. Chowdhury3 and
S. Datta1
1) Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, 2) Department of Tropical
Medicine, Calcutta School of Tropical Medicine and 3) Department of Hepatology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical
Education and Research, Kolkata, IndiaAbstractAn important driving force behind the sequence diversity of hepatitis B virus (HBV) is viral adaptation to host immune responses. To gain an
insight into the impact of host immunity on genetic diversiﬁcation and properties of HBV, we characterized HBV of genotype D from
treatment-naive hepatitis B e antigen-positive (EP) and hepatitis B e antigen-negative (EN) patients with chronic hepatitis B (CHB), where
HBV is under stronger immune pressure, with that of HBV derived from human immunodeﬁciency virus (HIV)/HBV-coinfected
individuals, where HIV infection has signiﬁcantly weakened the immune system. Full-length sequence analysis showed that HBV
heterogeneity was most extensive in EN-CHB followed by EP-CHB and HIV/HBV coinfection. The relative magnitude of non-synonymous
changes within B-cell epitopes was greater than that in T-cell epitopes of HBV open reading frames (ORFs) in both EP-CHB and EN-
CHB. Nine amino acid substitutions were identiﬁed in B-cell epitopes and one in a T-cell epitope of HBV in EN-CHB, most of which
resulted in altered hydrophobicities, as determined using the Kyte and Doolittle method, relative to wild-type residues found in HBV
from the HIV-positive group. Additionally, 19 substitutions occurred at signiﬁcantly higher frequencies in non-epitope regions of HBV
ORF-P in EN-CHB than HIV/HBV-coinfected patients. In vitro replication assay demonstrated that the substitutions, particularly in reverse
transcriptase and RNaseH domains of ORF-P, resulted in a decline in replication capacity of HBV. Hence, our results indicate that HBV
adapts to increasing immune pressure through preferential mutations in B-cell epitopes and by replicative attenuation. The viral epitopes
linked to immune response identiﬁed in this study bear important implications for future HBV vaccine studies.
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p://dx.doi.org/10.1016/j.cmi.2015.03.004IntroductionHepatitis B virus (HBV) is a non-cytopathic DNA virus that
causes liver injury by eliciting the host immune response against
viral antigens [1]. It replicates its genome via an error-prone
reverse transcription that provides an increased opportunity
for accumulation of mutations across its four overlapping open
reading frames (ORFs), pre-S1/pre-S2/S, pre-C/C, P and X [2].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Mondal et al. Immune adaptation in HBV of genotype D 710.e12However, the appearance and persistence of these mutations is
uniquely linked to the repertoire of antiviral responses exerted
by the B-cell and T-cell arms of the host immune system, which
favours the selection of viral variants that can escape immune
recognition and have better adaptation in the host. Most HBV
proteins have been shown to be targets for cytotoxic T (Tc),
helper T (Th) and B cells [1], each of which recognize and
interact with their cognate peptide epitopes.
Chronic HBV infection (CHI) is a highly heterogeneous
disease with marked variation in immune reactivity, virus
replication and liver disease activity [3]. The immune-active
phase of CHI can be classiﬁed as hepatitis B e antigen
(HBeAg)-positive (EP) or HBeAg-negative (EN) chronic
hepatitis B (CHB) depending on HBeAg status and patients
in either phase typically featured high HBV DNA and liver
enzymes (alanine aminotransferase and aspartate amino-
transferase) in sera and increased histological activity,
reﬂecting immune-mediated lysis of infected hepatocytes
[3]. High rates of nucleotide and amino acid changes had
been reported in HBV from both EP-CHB and EN-CHB
patients [2,4]; however, the extent of genetic diversity in
HBV that results from host immune pressures remains
unclear, unlike in human immunodeﬁciency virus (HIV) or
hepatitis C virus infection, where immune-driven escape
mutations have been well-studied [5,6]. Different studies
suggest that approximately 10% of HIV-infected patients
have chronic HBV coinfection because of shared trans-
mission routes [7]. HIV infection is known to severely
impair the host immune network and HIV/HBV coinfection
represents a fruitful setting for studying the impact of host
immunity on the heterogeneity of HBV. An ineffective
immune response during HIV/HBV coinfection implies that
HBV in such individuals would be minimally subjected to
immune selection, resulting in a homogeneous population
of wild-type HBV, whereas the emergence of a new
constellation of HBV mutants would coincide with
enhanced immune activation, as in active hepatitis. Hence
in the present study, we characterized full-length HBV
against the backdrop of different host immunological milieu
that encompassed the minimal immune reactivity state
encountered in HIV/HBV coinfection to a stronger and
more pronounced immune-active phase represented in
both EP-CHB and EN-CHB, to identify the genetic features
and properties of HBV that can be attributed to host im-
mune responses. To avoid the potential impact of
genotype-speciﬁc differences in HBV, we restricted our
analysis to HBV of genotype D (HBV/D), the most ubiq-
uitous of all HBV genotypes [8] and also the most preva-
lent genotype in India [9], for which little information was
available on immune-mediated diversity.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeMaterials and methodsPatients
Treatment-naive patients with CHB in the immune-active EP
phase (EP-CHB; n = 17), with hepatitis B surface antigen
(HBsAg) and HBeAg positivity (>6 months), alanine amino-
transferase levels >40 IU/L, serum HBV DNA >104 copies/mL
and histologically documented moderate to severe necroin-
ﬂammation (histological activity index 4–7), were recruited
from Hepatology Clinic of School of Digestive and Liver Dis-
eases (SDLD), Institute of Post Graduate Medical Education and
Research (IPGMER), Kolkata, India. We also included well-
characterized, treatment-naive, immune-active EN-CHB pa-
tients (n = 13) from SDLD, who participated in our previous
study [2]. In both cases, patients with HIV, hepatitis C virus or
hepatitis δ virus infection, or possessing co-morbidities like
diabetes mellitus, chronic alcoholism, intravenous drug abuse,
or subjected to any prolonged (>7 days) drug therapy or
showing evidence of cirrhosis and hepatocellular carcinoma
were excluded. Additionally, treatment-naive patients with
chronic HIV/HBV coinfection (n = 16) were recruited from the
outpatient facility of Calcutta School of Tropical Medicine
(CSTM), Kolkata. Blood samples were drawn from all partici-
pants with their written informed consent. The study was
approved by Ethical Review Committees of IPGMER and CSTM.
Testing of liver enzymes, HBV serological markers and
CD4 counts
Sera separated from blood samples were tested for alanine
aminotransferase/aspartate aminotransferase levels and sero-
logical markers, HBsAg, HBeAg and anti-HBe using commer-
cially available kits. To determine absolute CD4+ Th cell counts,
EDTA blood was processed using CD3/CD8/CD45/CD4 Mul-
titest reagent (BD Biosciences, San Jose, CA, USA) according to
the manufacturer’s guidelines and acquired on a BD FACSCa-
libur ﬂow cytometer.
HBV DNA isolation and quantiﬁcation
HBV DNA was extracted from 200 μL sera using QIAamp
DNA Blood Mini Kit (Qiagen Inc., Valencia, CA, USA) and
reconstituted in 30 μL water (molecular biology grade). Viral
load was determined by real-time PCR using SYBR Green PCR
Master mix (Applied Biosystems, Foster City, CA, USA) and
primer-pair F4-R3 (see Supporting information, Table S1), the
lower detection limit being 250 copies/mL.
Ampliﬁcation and sequencing of HBV genome
Full-length HBV-DNA was ampliﬁed by a one-step PCR method
using primers P1–P2 (see Supporting information, Table S1).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
710.e13 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIFor samples with low HBV DNA, second-round nested-PCR
was performed with two different primer-pairs, MP1–R5 and
F3–MP2 (see Supporting information, Table S1) that generated
two overlapping fragments covering the entire HBV genome.
Technical details of both PCR methods are reported in the
Supporting information. All PCR products were puriﬁed using a
QIAquick PCR puriﬁcation kit (Qiagen) and sequenced directly
with different internal primers (see Supporting information,
Table S1) using a BigDye terminator v3.1 cycle sequencing kit
(Applied Biosystems) on an automated DNA sequencer (ABI
Prism 3130). Sequence editing and analysis were performed by
SEQSCAPE V2.5 software.
Sequence analysis
Complete HBV sequences from different patients were
compared with representative sequences of HBV genotypes
A– J retrieved from GenBank. Alignments were carried out
using CLUSTAL_X software and the phylogenetic tree was
constructed by neighbour-joining method using MEGA5 soft-
ware. To conﬁrm the reliability of phylogenetic tree analysis,
bootstrap re-sampling and reconstruction were carried out
5000 times. For all HBV ORFs, pairwise estimates of the
number of synonymous substitutions/synonymous site (dS) and
the number of non-synonymous substitutions/non-synonymous
site (dN) were computed using a modiﬁed Nei–Gojobori model
with Jukes–Cantor correction as implemented in MEGA5.
Values of dS and dN were estimated for all published Tc-, Th-
and B-cell epitopes of HBV [2,10–12], along with overlapping
epitope and non-epitope regions. HBV sequence variability in
different patient groups was analysed with the help of multiple
alignment data.
Hydrophobicity plot
Hydrophobicity proﬁles of epitope regions of HBV proteins
were investigated using values normalized between 0 and 1 by
Kyte–Doolittle plot using PROTSCALE program in EXPASY, Bio-
informatics Resource Portal. A sliding window of ﬁve amino
acids with a step size of 1 was applied.
In vitro replication assay
An 1802-bp fragment (nucleotides 3164–1783) of ORF-P was
ampliﬁed with primers F4-R10 (see Supporting information,
Table S1) from each of the two full-length clones of HBV,
derived from an HIV/HBV-coinfected patient and an EN-CHB
patient, respectively, and digested using AvrII and NcoI restric-
tion enzymes (Fermentas, Burlington, ON, Canada) to generate
a 1194-bp fragment that included part of reverse transcriptase
(rt) and RNaseH (rh) domains (rt 17–344 and rh 1–70 amino
acids). Both of these 1194-bp fragments were then individually
used to replace the corresponding region of another plasmid,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectpTriEX-Mod-HBV-D containing replication competent 1.1×-
unit-length genome of HBV/D (a kind gift from Prof. Fabien
Zoulim, INSERM, France) [13]. Hence, two constructs, pTriEX-
Mod/HBV-D-EN and pTriEX-Mod/HBV-D-HIV were generated
that were isogenic except for their rt and rh domains. pTriEX-
Mod/HBV-D-EN and pTriEX-Mod/HBV-D-HIV were separately
transfected into HuH7 cells using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA, USA) along with pRL-CMV vector
(Promega, Madison, WI, USA), which served as transfection
normalization control. Forty-eight hours post-transfection, the
cells were harvested and some were lysed with lysis buffer
(50 mM Tris–HCl pH 8.0; 1 mM EDTA; 1% Nonidet P40) and
HBV DNA was isolated from intracellular core particles as
described previously [13]. With the remaining cells, luciferase
assay was performed using a Luciferase Reporter Assay kit
(Promega). HBV DNA from core particles was quantiﬁed by
real-time PCR and HBsAg was measured from culture super-
natants by a BeneSphera HBsAg Microwell ELISA kit (Avantor
Performance Materials, Deventer, the Netherlands). The ex-
periments were carried out four times in triplicates and results
were normalized to Renilla luciferase readings.
Statistical analysis
All analyses were performed using GRAPHPAD PRISM statistical
software version 5.0. The clinical variables were expressed as
median (range) or mean ± standard error mean (SEM) or
mean ± standard deviation (SD) as appropriate. The genetic
diversity between different groups was compared using two-
way analysis of variance test. Fisher’s exact test was per-
formed to make pairwise group comparisons of mutation fre-
quencies. For all tests, p values <0.05 was considered
signiﬁcant.
Nucleotide sequence accession numbers
The nucleotide sequences of HBV/D from HIV/HBV-coinfected,
EP-CHB and EN-CHB patients are available on the GenBank
database (http://www.ncbi.nlm.nih.gov/GenBank/index.html)
under accession numbers KM524349–KM524361,
KM524336–KM524348 and JN664923– JN664935,
respectively.ResultsDemographic, clinical and virological proﬁles of
patients
The demographic, clinical and virological characteristics of all
study subjects are listed in Table 1. Liver enzymes were found
to be signiﬁcantly elevated in EP-CHB and EN-CHB patients
compared with HIV/HBV coinfection, whereas HBV-DNA levelious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
TABLE 1. Clinical, demographic and biochemical data of different groups of patients
Patient groups Mann–Whitney test
EN-CHB, EP-CHB, HIV-HBV, p1 p2 p3
n [ 13 n [ 17 n [ 16
(EN-CHB vs.
HIV-HBV)a
(EN-CHB vs.
EP-CHB)a
(EP-CHB vs.
HIV-HBV)a
Age (years), median (range) 30 (14–66) 36 (10–72) 32.5 (23–47) ns ns ns
Sex, M:F 9:4 13:4 14:2 ns ns ns
HBeAg 0 17 12 <0.0001 <0.0001 0.04
Anti-HBe 10 2 3 0.007 0.005 ns
ALT (IU/L), median (range) 47 (45–104) 59 (42–99.1) 28 (13–56) 0.0007 ns 0.0002
AST (IU/L), median (range) 51.5 (45–103) 60 (44–96) 42.5 (12–49) 0.001 ns 0.0003
HBV DNA (copies/mL),
median (range)
3.1 × 105
(1.2 × 104 to 4.5 × 107)
7.8 × 105
(1.7 × 104 to 1.8 × 108)
9.1 × 107
(2.4 × 105 to 7.6 × 108)
0.0001 ns 0.05
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; EN-CHB, hepatitis B e antigen-negative patients with chronic hepatitis B; EP-CHB, hepatitis B e
antigen-positive patients with chronic hepatitis B; HBV, hepatitis B virus; HIV, human immunodeﬁciency virus; IU, international unit.
aMann–Whitney test, p value; ns, statistically not signiﬁcant.
CMI Mondal et al. Immune adaptation in HBV of genotype D 710.e14was signiﬁcantly higher in HIV/HBV-coinfected patients than in
the other two groups. However, the biochemical and virolog-
ical parameters did not differ among EP-CHB and EN-CHB
patients. As expected, the mean CD4+ Th-cell counts in HIV/
HBV-coinfected patients (164.9 ± 32.3 cells/mm3) were signif-
icantly lower than in EP-CHB and EN-CHB patients
(762.5 ± 67.5 cells/mm3).
Genotypic distribution
Phylogenetic analysis of complete HBV sequences from 16 HIV/
HBV-coinfected and 17 EP-CHB patients revealed that in each
case, 13 isolates belonged to genotype D, two were of geno-
type A and the remaining one from HIV/HBV and two from EP-
CHB were clustered with genotype C (see Supporting infor-
mation, Fig. S1). However, all 13 EN-CHB patients carried
HBV/D. Of the 13 HIV/HBV patients carrying HBV/D, ten were
positive for HBeAg and the rest were HBeAg-negative. Subse-
quent analyses were carried out exclusively on HBV/D isolates
that comprised 13 strains each from EP-CHB, EN-CHB and
HIV/HBV-coinfected patients.
Nucleotide diversity
The dS and dN, estimated for each HBV/D ORF and their
epitope/non-epitope regions by pairwise comparison of viral
sequences from each patient group, illustrated an overall sub-
stitution trend of dS>dN, indicating that most HBV genomic
regions showed strong signatures of purifying selection (see
Supporting information, Table S2). However, the dN/dS ratio in
epitope regions of ORF-X in EP-CHB and EN-CHB and ORF-S
in EP-CHB exceeded unity, suggesting that these regions were
subjected to positive selection (Fig. 1; see Supporting infor-
mation, Table S2). Notably, there was a substantial heteroge-
neity in the mean dN and dS values, with HBV/D from EN-CHB
exhibiting higher values than the other two groups. Of the
different epitopes (Tc/Th/B cells) of all HBV ORFs, the highest
dN values corresponded to regions that harbour the B-cellClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeepitopes and the mean dN of the B-cell epitope region was
signiﬁcantly higher in HBV sequences of EP-CHB and EN-CHB
than in those with HIV infection (Fig. 1; see Supporting infor-
mation, Table S2).
Mutational proﬁles of HBV/D in EP-CHB, EN-CHB and
HIV/HBV coinfection
ORF-PreS1/PreS2/S. Amino acid sequences of surface proteins
deduced from the nucleotide sequences of HBV in different
patient categories revealed the presence of ﬁve prominent
substitutions in epitope regions that occurred at high fre-
quencies in EN-CHB, followed by EP-CHB but were absent/
rare in HIV/HBV coinfection (Table 2). Of these, N103D in the
B-cell epitope of PreS1 was signiﬁcantly high in both EN-CHB
and EP-CHB relative to HIV/HBV-coinfected cases, whereas
A28R and T11A in overlapping B/Th/Tc-cell epitope regions of
PreS1 and PreS2, respectively, were associated with EN-CHB
compared with the other groups. The other substitutions,
S85A in B-cell epitopes of PreS1 and R48K in the Tc-cell
epitope of PreS2 had signiﬁcantly higher prevalence in EN-
CHB compared with HIV/HBV coinfection whereas their fre-
quencies were comparable in EN-CHB and EP-CHB as well as
between EP-CHB and HIV/HBV coinfection (Table 2). Sur-
prisingly no prominent substitution was detected in the epitope
region of ORF-S in all groups. Additionally, three substitutions
in non-epitope regions, I74L in PreS1 and S43L and L54P in
PreS2, were more frequently encountered in HBV from EN-
CHB than in HIV-positive patients.
ORF-X. Substitutions F30V, T36S, V92I and A110Q within B-
cell (amino acids 29–48, 89–112) and overlapping B/Tc-cell
(amino acids 91–100) epitope regions of X protein were
observed at higher rates in EN-CHB than in HIV/HBV-
coinfected patients whereas no signiﬁcant differences in their
frequencies were perceived in EP-CHB and HIV/HBV coin-
fection (Table 2).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
FIG. 1. dS (the number of synonymous substitutions per synonymous site) and dN (the number of non-synonymous substitutions per non-synonymous
site) of four hepatitis B virus open reading frames (HBV-ORFs) (PreS1/PreS2/S, X, C, and P) (a–d) and their epitope (B-, cytotoxic T (Tc) and helper T
(Th) cells) and non-epitope regions (e) in three groups of patients (hepatitis B e antigen-negative patients with chronic hepatitis B (EN-CHB), hepatitis
B e antigen-positive patients with chronic hepatitis B (EP-CHB) and human immunodeﬁciency virus/HBV coinfection). Results were shown in
mean ± SEM. Two-way analysis of variance p values; *p < 0.05; **p < 0.01; ***p < 0.001.
710.e15 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIORF-C. A single substitution, I116L in the B-cell epitope of core
protein occurred at high frequency in EN-CHB patients in
comparison with both HIV/HBV-coinfected and EP-CHB groups
(Table 2).
ORF-P. A total of 19 substitutions in non-epitope regions of HBV
polymerase (including three substitutions in terminal proteinClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(tp), ﬁve in spacer (sp), eight in rt and three in rh domains)
were detected at a signiﬁcantly high proportion in EN-CHB
compared with the HIV/HBV-coinfected group (Table 2).
Seven of these substitutions occurred at comparable fre-
quencies in EN-CHB and EP-CHB but the remaining 12 were
more abundant in EN-CHB. As the PreS/S-ORF completely
overlaps ORF-P, two substitutions, A28R and I74L in PreS1ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
TABLE 2. Frequencies of substitutions across the complete genome of HBV of genotype D derived from different patient group
Site of HBV Patient groups Fisher exact test
Types of
epitopeAmino acid substitution
EN-CHB, EP-CHB, HIV-HBV, p1 p2 p3
n [ 13, (%) n [ 13, (%) n [ 13, (%)
(EN-CHB vs.
HIV-HBV)a
(EN-CHB vs.
EP-CHB)a
(EP-CHB vs.
HIV-HBV)a
ORF-PreS1/PreS2/S
PreS1 A28R 9 (69.2) 1 (7.7) 0 (0) 0.0005 0.003 0.999 B-/Th-/Tc-cell
PreS1 I74L 11 (84.6) 5 (38.5) 5 (38.5) 0.041 0.041 1 non-epitope
PreS1 S85A 6 (46.2) 2 (15.4) 0 (0) 0.015 0.201 0.479 B-cell
PreS1 N103D 8 (61.5) 5 (38.5) 0 (0) 0.0016 0.433 0.039 B-cell
PreS2 T11A 8 (61.5) 2 (15.4) 1 (7.7) 0.01 0.041 0.999 B- & Th-cell
PreS2 S43L 5 (38.5) 2 (15.4) 0 (0) 0.04 0.378 0.479 non-epitope
PreS2 R48K 6 (46.2) 2 (15.4) 0 (0) 0.015 0.201 0.479 Tc
PreS2 L54P 7 (53.8) 2 (15.4) 0 (0) 0.005 0.097 0.479 non-epitope
ORF-X
F30V 7 (53.8) 3 (23.1) 0 (0) 0.005 0.226 0.219 B-cell
T36S 7 (53.8) 4 (30.8) 1 (7.7) 0.03 0.428 0.322 B-cell
V92I 6 (46.2) 2 (15.4) 0 (0) 0.015 0.201 0.479 B-/Tc-cell
A110Q 5 (38.5) 2 (15.4) 0 (0) 0.04 0.378 0.479 B-cell
ORF-C
cI116L 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 B-cell
ORF-P
tpS78T 6 (46.2) 4 (30.8) 0 (0) 0.015 0.688 0.096 non-epitope
tpK90N 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 non-epitope
tpR164H 11 (84.6) 8 (61.5) 5 (38.5) 0.041 0.378 0.434 non-epitope
spG58R 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 non-epitope
spF59V 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 non-epitope
spS72A 7 (53.8) 1 (7.7) 0 (0) 0.005 0.03 0.999 non-epitope
spL88S 6 (46.2) 1 (7.7) 0 (0) 0.015 0.073 0.999 non-epitope
spF104S 9 (69.2) 2 (15.4) 0 (0) 0.0005 0.015 0.479 non-epitope
rtA7T 6 (46.2) 5 (38.5) 0 (0) 0.015 1 0.039 non-epitope
rtN123D 7 (53.8) 2 (15.4) 0 (0) 0.005 0.097 0.479 non-epitope
rtN248H 11 (84.6) 6 (46.2) 1 (7.7) 0.0002 0.097 0.073 non-epitope
rtY257W 8 (61.5) 2 (15.4) 1 (7.7) 0.01 0.041 0.999 non-epitope
rtQ267H 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 non-epitope
rtI269L 8 (61.5) 2 (15.4) 0 (0) 0.0016 0.041 0.479 non-epitope
rtS317A 7 (53.8) 2 (15.4) 0 (0) 0.005 0.097 0.479 non-epitope
rtL336M 9 (69.2) 2 (15.4) 0 (0) 0.0005 0.015 0.479 non-epitope
rhP2S 8 (61.5) 2 (15.4) 1 (7.7) 0.01 0.041 0.999 non-epitope
rhL30Q 8 (61.5) 2 (15.4) 1 (7.7) 0.01 0.041 0.999 non-epitope
rhL55I 10 (76.9) 2 (15.4) 4 (30.8) 0.047 0.005 0.644 non-epitope
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; EN-CHB, hepatitis B e antigen-negative patients with chronic hepatitis B; EP-CHB, hepatitis B e
antigen-positive patients with chronic hepatitis B; HBV, hepatitis B virus; HIV, human immunodeﬁciency virus; IU, international unit; ORF, open reading frame; Tc, cytotoxic T; Th, T
helper.
aFisher exact test, p value.
CMI Mondal et al. Immune adaptation in HBV of genotype D 710.e16corresponded to two additional changes, spR31Q and spN77T
respectively in ORF-P and had distribution patterns identical to
those of PreS1 variants in the study groups.
Promoter/regulatory regions. HBV gene expression is controlled
by two enhancers (Enh-I and Enh-II) and four promoters [2].
The basal core promoter (BCP) of HBV from EN-CHB, EP-
CHB and HIV/HBV-coinfected subjects showed no signiﬁcant
difference with respect to the commonly described mutations,
A1762T and G1764A that caused reduced HBeAg expression.
However, another BCP mutation, C1845T along with eight
mutations in overlapping X promoter/Enh-I region, three in
PreS1 promoter and one each in PreS2/S promoter and Enh-II
were found to be signiﬁcantly higher in EN-CHB than in the
HIV/HBV group (see Supporting information, Table S3).
Hydrophobicity plot
The binding of antigens to antibodies or T-cell receptors de-
pends on electrostatic and hydrophobic interactions, hydrogen
bonds and van deer Waals forces, which are critical for theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeexquisite speciﬁcity observed in immunological interactions.
We examined the impact of amino acid substitutions within the
immune epitopes of HBV proteins on the hydrophobicity
proﬁle of the speciﬁc epitope regions by the Kyte–Doolittle
method. Most of the substitutions, described in Table 2,
resulted in variations in epitope hydrophobicities relative to
wild-type residues, with the exception of V92I and I116L in B-
cell epitopes of X and core, respectively, where no differences
were noted. However, the most profound effects on epitope
hydrophobicities were observed with respect to the sub-
stitutions A110Q in B-cell epitope of X and A28R in over-
lapping B/T-cell epitopes of PreS1 (Fig. 2).
Replication capacity
We investigated whether the substitutions detected in ORF-P,
particularly in the rt and rh domains, affect the replication ca-
pacity of HBV in comparison to the isolates lacking these sub-
stitutions. HBV constructs, pTriEX-Mod/HBV-D-EN and
pTriEX-Mod/HBV-D-HIV, differing only in rt and rh domains,ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
FIG. 2. Hydrophobicity plots of
epitope regions of hepatitis B virus
open reading frames (HBV-ORFs),
(a) X and (b) PreS1 showing altered
hydrophobicity due to substitutions
at speciﬁc positions, obtained by the
Kyte and Doolittle method using
PROTSCALE program in EXPASY.
Values were normalized between
0 and 1, and a sliding window of ﬁve
amino acids with a step size of 1 was
applied.
710.e17 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIwere generated, such that pTriEX-Mod/HBV-D-EN harboured
seven of the eight substitutions (except rtA7T) in rt and all
three substitutions in rh domains that were found in high
proportions in HBV from EN-CHB (Table 2), whereas pTriEX-
Mod/HBV-D-HIV carried wild-type residues at analogous po-
sitions, as in HIV/HBV-coinfected patients. Transfection of
these constructs into a Huh7 cell line and quantiﬁcation of
intracellular core-associated HBV DNA indicated that HBV
expressed from pTriEX-Mod/HBV-D-EN had a mean approxi-
mately twofold lower replication efﬁciency than HBV from
pTriEX-Mod/HBV-D-HIV (p < 0.05) (Fig. 3). Consistent with
these data, an approximately 1.88-fold decrease in HBsAg was
noted in culture supernatant when pTriEX-Mod/HBV-D-EN
was used (Fig. 3).DiscussionFIG. 3. The effect of substitutions in reverse transcriptase (rt) and
RNaseH (rh) domains of open reading frame P (ORF-P) on hepatitis B
virus (HBV) replication capacity. The construct pTriEX-Mod/HBV-D-
EN harboured seven substitutions in rt and three substitutions in rh
domains while pTriEX-Mod/HBV-D-HIV carried wild-type residues at
analogous positions. The relative (a) intracellular HBV DNA level was
measured by quantitative real-time PCR and (b) hepatitis surface antigen
(HBsAg) level in culture supernatant was estimated by ELISA, after
normalization to Renilla luciferase, following transfection of these con-
structs in Huh7 cell line. Paired t-test p values; *p < 0.05.We investigated the immune-mediated changes in molecular
features of HBV/D by characterizing the virus derived from HIV/
HBV-coinfected patients, where HBV was under feeble immune
pressure, to that from CHB patients, where the prevailing host
immunity imposed a stronger selection on the virus. Under-
standing the sites and pathways of immune escape will be useful
in future vaccine design effort. In HIV/HBV coinfection, in the
absence of an effective immune response and no adaptation,
there is little potential for viral mutants to be advantageous and
the highest replicators dominate the virus population as evident
from higher HBV copy numbers in these patients relative to EP-
CHB or EN-CHB. The near-identity of HBV sequences from
HIV/HBV-coinfected patients, irrespective of HBeAg status,
allowed a consensus sequence to be derived and any deviation in
the setting of EP-CHB and EN-CHB had been presumed to
represent the imprints of in vivo immune selection pressure on
viral genome. Consistent with previous studies [9,14], our re-
sults revealed that HBV/D genomes in all patient categoriesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectexhibited an abundance of synonymous changes implying that
purifying selection generally acted in the majority of HBV genes
although ORF-X showed evidence of positive selection
(dN > dS). However, a higher substitution rate was associated
with EN-CHB relative to EP-CHB and HIV/HBV coinfection,
suggesting that the loss of HBeAg resulted in increased immune
pressure on HBV and consequently favoured greater accumu-
lation of mutations in the viral genome. Chronologically EP-CHBious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
CMI Mondal et al. Immune adaptation in HBV of genotype D 710.e18occurs early in the natural history of CHI and follows the “im-
mune-tolerant” phase, typically experienced by individuals with
perinatal/early childhood acquired HBV infection and charac-
terized by high viraemia and HBeAg but feeble host immune
activity and minimal inﬂammation [3]. However, as the host
immune system matures, changes in the intrahepatic pro-
inﬂammatory environment might allow immune activation
against HBV and hepatocellular injury to ensue, ushering in EP-
CHB [15]. A gradual rise in host immune pressure in EP-CHB
was reﬂected in increasing trend of dN in all HBV-ORFs
compared with HIV/HBV coinfection, although in most cases,
the difference did not reach statistical signiﬁcance. In terms of
individual substitutions, we identiﬁed only one epitopic mutation
that was signiﬁcantly higher in EP-CHB than HIV/HBV coinfec-
tion, as opposed to 13 such mutations in EN-CHB, suggesting
that immune pressure is less profound in EP-CHB, which limited
the selection of mutants. EN-CHB, representing a later immune-
reactive phase in the natural course of CHI, may follow sero-
conversion from HBeAg to anti-HBe or may develop after years
of inactive carrier state or may be associated with emergence of
PreC/BCP mutations that affect HBeAg expression [2,3]. It had
been demonstrated that HBeAg preferentially elicits an anti-
inﬂammatory Th2-like immune response and promotes the
suppression of HBeAg/HBcAg-speciﬁc Tc cells [16]. But this
phenomenon is reversed during HBeAg seroconversion [17]
and immune activity is likely to become heightened during EN-
CHB, which in turn fostered a greater variability in HBV and
contemporaneous selection of mutations.
The sites in viral genome mapping to B-cell epitopes were
found to be consistently more variable than T-cell epitopes in
HBV from both EN-CHB and EP-CHB. Although selection of
mutations within Tc epitopes of HBV/B and HBV/C during
CHI had been reported earlier [18,19], our analysis of com-
plete HBV/D sequences demonstrated that variation in T-cell
epitopes was not a common event in CHB. Whereas in acute
infection, T-cell response to HBV is vigorous, polyclonal and
multi-speciﬁc, it is weak and narrowly targeted in CHI [16] and
hence less likely to select for escape mutations at epitope
sites. Recent studies have documented the ability of escape
mutations to revert back to consensus residues upon trans-
mission to new hosts, particularly those with discordant HLA
types [20]. Given the heterogeneity in HLA alleles in Indian
populations [21], there is a possibility that some T-epitope
mutations may revert following transmission to HLA-
mismatched hosts, which in turn may account for their low
prevalence in HBV of different CHB patients. The only Tc
epitope mutation, R48K in PreS2 detected in this study was
also perceived in HBV/A from HIV/HBV-coinfected patients of
South Africa [22] and in HBV/D from an HBeAg-positive
asymptomatic carrier and an EN-CHB patient of EasternClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeIndia [23]. In contrast to the gradual T-cell exhaustion re-
ported during CHI, the majority of CHB patients had been
found to carry a substantial proportion of activated B cells in
both the naive and memory B-cell pools [24]. Hence focused
substitutions in B-cell epitopes seem to represent an impor-
tant escape strategy for HBV during CHI. Our results agree
with those of Carman et al. [25] where mutations were pre-
dominantly seen in B-cell epitopes of HBV core protein in anti-
HBe-positive patients with ongoing disease. Of the different B-
cell epitope mutations described here, F30V in X was previ-
ously reported in HBV/D from a child of an HBV-infected
mother who acquired breakthrough infection, despite
receiving hepatitis B immunoglobulin and vaccine series [26].
Other substitutions in B-cell epitopes, namely, I116L in core
protein, were earlier observed in Spanish CHB patients [27],
S85A in PreS1 was noted in an HBsAg-positive cirrhotic pa-
tient from Italy [28], in an EN-CHB patient and an HBeAg-
positive asymptomatic carrier of Eastern India [23], whereas
N103D in PreS1 was encountered in occult HBV from HBsAg-
negative Italian patients with hepatocellular carcinoma [28]
and in Iranian patients with HBV-related hepatocellular carci-
noma [29], all infected with HBV/D. The interaction of epi-
topes with the presenting HLA molecule, T-cell receptor or
antibodies can be severely impacted even by subtle changes in
amino acid sequences of the epitopes, allowing the virus to
evade immune recognition. The analysis of epitope regions
with and without these substitutions showed changes in their
hydrophobicity proﬁles, suggesting that these substitutions
may affect the recognition of viral immune targets by speciﬁc B
or T cells. However, functional studies demonstrating the
failure of these different mutated T-/B-cell epitopes to trigger
an effective immune response need to be performed.
When non-epitope regions of HBV-ORFs were considered,
ORF-P exhibited a higher frequency of substitutions in EN-CHB
and EP-CHB patients than HIV/HBV coinfection. In vitro repli-
cation assay demonstrated that mutations, particularly in rt and
rh domains, signiﬁcantly reduced the replication efﬁciency of
HBV. Grossman et al. [30] had proposed a general theory on
the sensitivity of immune response to antigenic stimulation,
according to which the immune system tends to respond to
strong perturbations caused by rapid increase in antigen
appearance and by inﬂammation but adapts to and/or tolerates
slow changes. Hence a rapidly replicating virus by generating a
larger pool of peptides could be an easy target for the immune
system. In contrast, a more slowly replicating virus, like HBV
from EN-CHB carrying different mutations in ORF-P, appear to
be more difﬁcult to control and by underwhelming the immune
response of the host it could sneak through immune surveil-
lance and would be more successful in establishing a persistent
infection.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 710.e11–710.e20
710.e19 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMICollectively, our study highlights that increasing immune
pressure favours the selection of HBV/D with lower replication
efﬁciency and altered B-cell epitopes. It also provides a
comprehensive appraisal of viral residues that showed high
propensity for adaptive changes in EP-CHB and EN-CHB that
would contribute towards future designing of immune-based
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